Similar treatment strategies are currently under development for ALS patients with FUS and ATXN2 mutations (NCT04768972, NCT04494256) and might further revolutionize the ALS treatment landscape. The gene discussed is ATXN2; the disease is amyotrophic lateral sclerosis.